Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi : bolsters its position on multiple sclerosis with a $765M BTK licensing deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 05:12pm CET

Sanofi is snapping up an early-stage program from San Franciscos Principia Biopharma, shoring up the pharma giants position in multiple sclerosis.

Sanofi will write a check for $40 million upfront, with future milestone payments that could total $765 million. In return, Sanofi gets a worldwide license to develop and sell PRN2246. The asset, which just entered Phase I clinical trials, is a BTK inhibitor designed to access the brain and spinal column by crossing the blood-brain barrier. Once there, its meant to impact immune cell and brain cell signaling. The companies hope this may treat MS and other central nervous system diseases.

The asset makes sense for Sanofi, as the drug maker already has two successful MS drugs on the shelves: Aubagio and Lemtrada. The two products make up a significant part of Sanofis overall revenue.

Sanofis neuroscience research head Rita Balice-Gordon said the investment highlights Sanofis focus on MS and neurological disease.

Complementing our own internal R&D expertise, external relationships like this may accelerate delivery of new treatments to patients living with these serious diseases, Balice-Gordon said.

Principias CEO Martin Babler said partnering with a pharma giant with MS experience allows the startup to make better use of its resources.

The agreement allows Principia to maximize the BTK opportunity in neurology with a strong partner for PRN2246 while focusing internal resources on our lead BTK inhibitor in another therapeutic area, Babler said.

The companys lead program, PRN1008, is in Phase II trials in patients with pemphigus, an orphan autoimmune disease.

The deal between Sanofi and Principia is a tad open-ended. Principia has the option to co-fund Phase III development, should the asset progress that far. If they choose that option, they can get increased royalties on global sales or a profit and loss sharing agreement in the US.

The transaction is expected to close in the fourth quarter.

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
03:44p SANOFI : refunds gov't with P1.16-B for unused Dengvaxia
03:17p SANOFI : refunds P1.16-B worth of unused Dengvaxia
11:16a SANOFI : Appoints Dominique Carouge Executive Vice President Head of Business Tr..
01/19 SANOFI : Appoints Dominique Carouge Executive Vice President Head of Business Tr..
01/19 SANOFI : Researchers from Sanofi Pasteur Report Findings in Mycoplasma (Validati..
01/19 SANOFI : Researchers from Sanofi Pasteur Describe Findings in Rabies Virus (A no..
01/19 REGENERON PHARMACEUTICALS : and Sanofi To Accelerate and Expand Investment for C..
01/19 NEW DENGUE HEMORRHAGIC FEVER FINDING : Insights From Phase III...
01/18 SANOFI : EDITORIAL - Sober approach
01/18 SANOFI : NBI to submit initial result of probe on Dengvaxia mess
More news
News from SeekingAlpha
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/17 De-Risking Catalysts Aplenty - Cara Therapeutics
01/17 VERTEX PHARMACEUTICALS : Set To Wow In '18
01/16 WALL STREET BREAKFAST : More Records In Store For Equities
01/14 CDC : Worst flu season in years
Financials (€)
Sales 2017 35 761 M
EBIT 2017 9 145 M
Net income 2017 7 967 M
Debt 2017 5 749 M
Yield 2017 4,14%
P/E ratio 2017 11,54
P/E ratio 2018 16,05
EV / Sales 2017 2,74x
EV / Sales 2018 2,69x
Capitalization 92 146 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 29
Average target price 83,9 €
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI0.72%112 597
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132